Page 7 - Pharma Industry

Sun Pharma gets USFDA approval for new device to treat skin disease

The company says that the new device is more compact and easier to use than its predecessor

JB Pharma Q4 results: Profit up 15% to ₹145.6 cr; revenue rises 10%

JB Pharma posts strong FY25 performance with 19.3% profit growth; domestic business up 20%, CDMO segment and Russia drive international gains

Margin pressures, growth triggers to weigh on Dr Reddy's Laboratories

The stock has been an underperformer compared to peers not only in the short term (three months, and six months) but also in the longer term

US President Donald Trump's drug price slash could sting Indian pharma

Up to 80% US price cuts may squeeze margins, push up innovator drug costs

Trump's 'Make in America' push: Indian drug cos in no rush to make US shift

Pharma industry veteran said that the US wanting to encourage local production is a very natural thing to do

Alembic Pharma Q4 profit dips 12%, revenue rises 17% to Rs 1,770 cr

India branded business grows 8% in Q4FY25 with 4 product launches while Ex-US markets rise 43% and US segment delivers 20% growth during the quarter

Mutual Funds increased stake in 14 pharma stocks in Q4FY25; do you own any?

Analysts believe that pharma shares continue to see buying interest, given the inelastic demand for medicines; tariffs, if any could have minimal impact on the industry.

Indian pharma companies eye larger share of US cancer generics market

Indian firms have been focusing on complex generics for some time now, which insulates them partially from pricing pressures in the generics space in the US

Trump tariff plan: US Prez to announce levy on pharma imports soon

The pharmaceutical sector was previously spared by the Trump administration in the last round of tariffs that were announced on April 2

Trump tariffs drags Sensex 300pts amid volatility; IT, pharma in focus

While the Nifty IT index lost 4.21 per cent due to US recession fears, investors found comfort in the pharma sector, which was spared harsh treatment in the sweeping tariffs announced by US President

Trump's 27% tariff on Indian exports: Who gains and who takes the hit?

The US Trump administration has levied a flat 27% tariff on Indian goods with some exemptions. Here how domestic players have been impacted

Lupin announces acquisition of UK-Based Renascience Pharma for GBP 12.3 mn

Renascience, incorporated in 2015, supplies niche branded bio-generic products catering to primary and secondary care in the UK

India may soon train select countries on best drug regulatory practices

The project will be an extension of the CDSCO and NIHFW's ongoing training programmes with drug inspectors from the central and state drug authorities

Bharat Biotech launches India's only integrated cell, gene therapy facility

BBIL's 50,000-square-foot CGT facility advances its mission to deliver life-saving treatments for haematological malignancies and inherited blood disorders

Key diabetes drug price crashes by up to 90% as generics enter market

Mankind, Alkem, Glenmark launch generic versions of empagliflozin

Emcure Pharmaceuticals share gains on foraying into daily supplements space

The uptick in the Emcure Pharmaceuticals share price came after the company announced its entry into the daily supplements space with the expansion of its Arth range

Eliminate import duty on drugs from US: Pharma exporters to Centre

The exporters' worry is understandable as the US is the largest export market for Indian pharma accounting for 31.35 percent of India's overall pharma exports worth $27.8 bn

Senores Pharma to acquire 14 ANDAs from Dr Reddy's for US markets

Gujarat-based Senores Pharmaceuticals on Tuesday said it will acquire a basket of 14 Abbreviated New Drug Applications from Dr Reddy's Laboratories for an undisclosed amount. Senores Pharmaceuticals, Inc, USA, a subsidiary of the drug firm, has inked agreements with Dr Reddy's for acquiring the Abbreviated New Drug Applications (ANDAs), the company said in a statement. The basket includes 13 ANDAs approved by the USFDA (US Food and Drug Administration), with one application pending approval, it added. The addressable opportunity of the acquired ANDAs in the US is around USD 421 million as per IQVIA. Senores said the acquisition will be funded through the initial public offer proceeds. This is in line with the objects of the IPO stated in the Red Herring Prospectus, it added. Senores Pharmaceuticals MD Swapnil Shah said the acquired molecules span multiple therapeutic areas with growing consumption. The portfolio consists of controlled substances and the general category of produ

Indian pharma sector's regulatory violation instances fell 11% in '24

In 2014, the share of OAI status globally stood at 6 per cent which has now more than doubled standing at 14 per cent

Indian drugmakers to stay competitive despite US tariff plans: Dr Reddy's

The industry is still waiting for more clarity on any tariffs before taking any action, Prasad said on the sidelines of the BioAsia conference in the Southern Indian state of Telangana